MTOR and carcinosarcoma: Taking into consideration differences in mTOR pathway alterations between type I endometrial carcinoma and carcinosarcoma, supported by observed in present study resistance of carcinosarcoma cell lines to rapamycin, therefore comparing this studies seems to be doubtful.